Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online 
United Airlines Eyes Merger with American Airlines in Potential Industry-Shaping Deal 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
TSMC Posts Record Q1 2026 Profits Driven by Surging AI Chip Demand 
LIVONIA, Mich., June 01, 2017 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and NASH, today announced that management will provide a corporate update at LD Micro Invitational, taking place June 6-7 in Los Angeles, California, and at the Jefferies 2017 Global Healthcare Conference, taking place June 6-9, 2017, in New York City.
| LD Micro Invitational | |||
| Date: | Tuesday, June 6th | ||
| Time: | 4:00 pm Pacific Time | ||
| Presenter: | Charles Bisgaier, Ph.D., Chief Scientific Officer | ||
| Location: | Luxe Sunset Boulevard Hotel, Los Angeles, CA | ||
| Jefferies 2017 Global Healthcare Conference | |||
| Date: | Thursday, June 8th | ||
| Time: | 4:00pm Eastern Time | ||
| Presenter: | Lee Golden, MD, Chief Medical Officer | ||
| Location: | Grand Hyatt Hotel, Imperial Ballroom | ||
| Webcast: | http://wsw.com/webcast/jeff105/gemp | ||
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. We are focused on providing new treatment options for cardiometabolic diseases through our complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care especially statins that will benefit patients, physicians, and payors. Gemphire has 3 clinical trials ongoing for homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH)/atherosclerotic cardiovascular disease (ASCVD), and severe hypertriglyceridemia (SHTG) under NCT02722408, NCT02634151, and NCT02944383, respectively with a fourth planned trial in NASH in second half of 2017. Please visit www.gemphire.com for more information.
Contact: Andrew McDonald, Ph.D. LifeSci Advisors, LLC (646) 597-6987 Jeff Mathiesen, CFO Gemphire Therapeutics Inc. (734)-245-1700
